Scholarlink

Introduction <p>Hepatocellular carcinoma (HCC) is the 6th most common malignancy worldwide with variable prognostic outcomes. The neutrophil-to-lymphocyte ratio (NLR) has emerged as a potential prognostic marker, but its applicability across Barcelona Clinic Liver Cancer (BCLC) stages remains unclear. This study aims to assess the prognostic value of NLR in patients with HCC across different BCLC stages.</p> Materials and methods <p>We conducted a multicenter retrospective analysis of 312 HCC patients in BCLC stage 0-A diagnosed and treated between 2010 and 2016 in eight centers in Slovakia. Patients were divided into BCLC stages 0-A, B, and C and further stratified by NLR &lt; 1.5 and NLR ≥ 1.5.</p> Results <p>Overall survival (OS) and progression-free survival (PFS) were analyzed, with comparisons across stages and NLR subgroups. Patients with NLR &lt; 1.5 were trending toward improved OS in each BCLC stage, with significant differences observed in stages BCLC B (40.1 vs. 16.9&#xa0;months; <i>P</i> = 0.002) and BCLC C (18.93 vs. 5.78&#xa0;months; <i>P</i> = 0.0028). In BCLC stage B, NLR &lt; 1.5 was associated with a twofold increase in PFS compared to NLR ≥ 1.5 (40.1 vs. 16.9&#xa0;months; <i>P</i> = 0.061). BCLC stage C patients with NLR &lt; 1.5 achieved OS outcomes comparable to BCLC stage B patients with NLR ≥ 1.5 (18.9 vs. 16.9&#xa0;months; <i>P</i> = 0.71).</p> Conclusion <p>Lower NLR was associated with better survival outcomes across BCLC stages, supporting its use as a prognostic marker in HCC. Future prospective studies are needed to confirm these findings and to determine optimal NLR cut-offs for clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic Value of Neutrophil-to-Lymphocyte Ratio Across Barcelona Clinic Liver Cancer Stages in Hepatocellular Carcinoma: A Multicenter Retrospective Analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月24日

查看全文
  • Dominik Safcak,
  • Sylvia Drazilova,
  • Jakub Gazda,
  • Svetlana Adamcova Selcanova,
  • Lea Balazova,
  • Radovan Barila,
  • Slavomira Komárova,
  • Michal Mego,
  • Marek Rac,
  • Lubomir Skladany,
  • Miroslav Zigrai,
  • Martin Janicko,
  • Roman Zahorec,
  • Peter Jarcuska

摘要

Introduction

Hepatocellular carcinoma (HCC) is the 6th most common malignancy worldwide with variable prognostic outcomes. The neutrophil-to-lymphocyte ratio (NLR) has emerged as a potential prognostic marker, but its applicability across Barcelona Clinic Liver Cancer (BCLC) stages remains unclear. This study aims to assess the prognostic value of NLR in patients with HCC across different BCLC stages.

Materials and methods

We conducted a multicenter retrospective analysis of 312 HCC patients in BCLC stage 0-A diagnosed and treated between 2010 and 2016 in eight centers in Slovakia. Patients were divided into BCLC stages 0-A, B, and C and further stratified by NLR < 1.5 and NLR ≥ 1.5.

Results

Overall survival (OS) and progression-free survival (PFS) were analyzed, with comparisons across stages and NLR subgroups. Patients with NLR < 1.5 were trending toward improved OS in each BCLC stage, with significant differences observed in stages BCLC B (40.1 vs. 16.9 months; P = 0.002) and BCLC C (18.93 vs. 5.78 months; P = 0.0028). In BCLC stage B, NLR < 1.5 was associated with a twofold increase in PFS compared to NLR ≥ 1.5 (40.1 vs. 16.9 months; P = 0.061). BCLC stage C patients with NLR < 1.5 achieved OS outcomes comparable to BCLC stage B patients with NLR ≥ 1.5 (18.9 vs. 16.9 months; P = 0.71).

Conclusion

Lower NLR was associated with better survival outcomes across BCLC stages, supporting its use as a prognostic marker in HCC. Future prospective studies are needed to confirm these findings and to determine optimal NLR cut-offs for clinical practice.